Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abiomed gets US nod to continue AbioCor trial:

This article was originally published in Clinica

Executive Summary

Abiomed is pressing on with a clinical trial of its implantable replacement heart, AbioCor, after gaining permission from the US FDA to implant the device in another five patients. The trial will consist of a total of 15 patients, who will be assessed in groups of five. The FDA's decision comes shortly after the first patient enrolled in the trial suffered a stroke (see Clinica No 984, p 20). While noting that it has much to prove and learn, the Danvers, Massachusetts firm says that clinical results from the first five patients implanted with the device look "extremely promising".

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT074189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel